Xeris Biopharma Holdings, Inc.
XERS
$6.96
-$0.22-3.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.06% | 48.84% | 47.94% | 35.39% | 12.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.06% | 48.84% | 47.94% | 35.39% | 12.31% |
| Cost of Revenue | -19.11% | 52.73% | 46.17% | 25.20% | 65.75% |
| Gross Profit | 55.83% | 48.08% | 48.24% | 37.48% | 1.39% |
| SG&A Expenses | 3.31% | 11.00% | 14.69% | -9.39% | 20.60% |
| Depreciation & Amortization | 0.00% | 0.04% | -0.04% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.73% | 19.21% | 15.17% | -3.52% | 26.16% |
| Operating Income | 152.21% | 154.75% | 78.31% | 179.05% | -162.43% |
| Income Before Tax | 103.26% | 86.48% | 50.62% | 62.48% | -52.17% |
| Income Tax Expenses | -- | -- | -- | 100.00% | -883.43% |
| Earnings from Continuing Operations | 103.95% | 87.15% | 51.42% | 61.81% | -29.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.95% | 87.15% | 51.42% | 61.81% | -29.12% |
| EBIT | 152.21% | 154.75% | 78.31% | 179.05% | -162.43% |
| EBITDA | 199.04% | 244.69% | 99.42% | 259.24% | -445.28% |
| EPS Basic | 103.60% | 88.03% | 55.22% | 64.60% | -19.59% |
| Normalized Basic EPS | 102.94% | 87.86% | 56.10% | 105.75% | -69.85% |
| EPS Diluted | 103.18% | 88.03% | 55.22% | 64.60% | -24.58% |
| Normalized Diluted EPS | 102.69% | 87.86% | 56.10% | 105.75% | -69.85% |
| Average Basic Shares Outstanding | 9.84% | 7.49% | 8.49% | 7.94% | 7.92% |
| Average Diluted Shares Outstanding | 19.21% | 7.49% | 8.49% | 7.94% | 7.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |